Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free -hCG and pregnancy-associated plasma protein-A | Zendy

K. O. Kagan | Zendy; D. Wright | Zendy; Catalina Valencia | Zendy; Nerea Maíz | Zendy; K. H. Nicolaides | Zendy

Open Access

Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free -hCG and pregnancy-associated plasma protein-A

Author(s) -

K. O. Kagan,

D. Wright,

Catalina Valencia,

Nerea Maíz,

K. H. Nicolaides

Publication year - 2008

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/den224

Subject(s) - obstetrics , fetus , medicine , pregnancy , nuchal translucency measurement , pregnancy associated plasma protein a , nuchal translucency , trisomy , fetal heart , gynecology , prenatal diagnosis , first trimester , biology , genetics

A beneficial consequence of screening for trisomy 21 is the early diagnosis of trisomies 18 and 13. Our objective was to examine the performance of first-trimester screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency (NT) thickness, fetal heart rate (FHR) and maternal serum-free beta-hCG and pregnancy-associated plasma protein-A (PAPP-A).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research